血液病患者肝功能障碍时肝噬血现象的预后影响及肝活检联合噬血细胞综合征诊断评分(HScore)的价值
2016至2019年纳入110例血液系统恶性肿瘤合并肝功能障碍且诊断不明的患者,行116次肝活检(76次经颈静脉、40次经皮),肝活检安全且诊断效率高;肝噬血现象(HH)占56%,HH患者1年总生存(OS)为35% vs 无HH者58%(p=0.026)。HScore≥169者1年OS为24% vs HScore<169者50%(p=0.019)。
要点
- 血液病合并肝功能障碍且标准检查未明确诊断时,肝活检安全且诊断效率高,HH检出率56%。
- HH患者1年OS为35%,无HH者为58%(p=0.026),HH与不良预后相关。
- HScore≥169者1年OS为24%,HScore<169者为50%(p=0.019),HScore联合肝活检可能有助于完善噬血细胞综合征诊断。
核心结论
- 肝活检在血液病合并肝功能障碍患者中可行且诊断贡献显著,HH发生频繁且与不良预后相关。
- 联合肝活检,HScore可能有助于完善噬血细胞综合征诊断。
研究设计与样本
- 2016年至2019年间连续纳入110例血液系统恶性肿瘤合并肝功能障碍且诊断不明的患者,共行116次肝活检(经颈静脉76次、经皮40次)。
主要发现
- 主要诊断包括HH(56%)、移植物抗宿主病(55%)、相关感染(24%)、肝窦阻塞综合征(15%)和肿瘤浸润(8%)。
- 35%的患者病情危重,74%为异基因造血干细胞移植受者。
- HH患者1年OS为35% vs 无HH者58%(p=0.026)。
- HScore≥169者1年OS为24% vs HScore<169者50%(p=0.019)。
关键数值与推荐
- HH诊断比例56%,移植物抗宿主病55%,相关感染24%,肝窦阻塞综合征15%,肿瘤浸润8%。
- HH患者1年OS为35%,无HH者为58%(p=0.026)。
- HScore≥169者1年OS为24%,HScore<169者为50%(p=0.019)。
临床怎么用
- 原文结论认为肝活检在血液病合并肝功能障碍患者中可行且诊断贡献显著,HH发生频繁且与不良预后相关,联合肝活检HScore可能有助于完善噬血细胞综合征诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatic dysfunction (HD) is common in patients with haematological malignancies. Hepatic haemophagocytosis (HH) was detected in >50% of liver biopsies taken when HD remained unresolved after standard examination. We aimed to explore the contribution of liver biopsy in patients with both haematological malignancies and HD, describe the population of patients with HH, assess the prognostic impact of HH, and investigate haemophagocytic syndrome diagnostic score (HScore) utility in patients with HH. Between 2016 and 2019, 116 consecutive liver biopsies (76 transjugular, 40 percutaneous) were taken in 110 patients with haematological malignancy and HD (hyperbilirubinaemia, elevated transaminases, and/or cholestasis) and without a clear diagnosis. Liver biopsies were safe and diagnostically efficient. Predominant diagnoses included: HH (56%), graft-versus-host disease (55%), associated infections (24%), sinusoidal obstruction syndrome (15%), and tumoral infiltration (8%). Of patients, 35% were critically ill and 74% were allogeneic haematopoietic stem cell transplantation recipients, while 1-year overall survival (OS) was 35% with HH versus 58% without HH (p = 0.026). The 1-year OS was 24% with a HScore of ≥169 versus 50% with a HScore of <169 (p = 0.019). Liver biopsies are feasible in and contribute significantly to haematology patients with HD. HH occurred frequently and was associated with a poor prognosis. Combined with liver biopsy, the HScore may be helpful in refining haemophagocytic syndrome diagnosis.
引用
- Bris PN, Gauchez P, Devillier R, et al. Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore). Br J Haematol. 2022. PMID: 35968907. doi:10.1111/bjh.18382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。